Navigation Links
Honeywell and Pro-Lab Sign Distribution Agreement for Laboratory Chemicals in Turkey
Date:12/3/2009

SEELZE, Germany, Dec. 3 /PRNewswire/ -- Honeywell (NYSE: HON) announced today a multi-year distribution agreement with Pro-Lab Laboratuar Teknolojileri, which will distribute Honeywell's Burdick & Jackson® high-purity solvents in Turkey.

Burdick & Jackson solvents are used extensively by biotechnology and pharmaceutical companies in the drug discovery and evaluation process.

"The annual growth rate of the Turkish pharmaceutical market is estimated to be between 8 percent and 9 percent in the next four years. This places Turkey among the high-potential pharmaceutical markets in the region, and we are glad to be have a strong partner there," said Daniel Nott, the regional leader for Honeywell's Health Care and Packaging business in Europe, Middle East and Africa. "This agreement will further help position us as a leading company in providing a wide range of high-purity solvents for research and development in the region."

Pro-Lab, based in Istanbul, is a leading distributor of a wide range of materials and equipment for laboratories in Turkey. Gokhan Aydogan, general manager of Pro-Lab, said both companies aim to provide quality offerings and high levels of service to the high-purity solvents market in Turkey. "We believe there are a lot of untapped opportunities to be explored, especially in the booming pharmaceutical industry," Aydogan said.

Honeywell's high-purity solvents are critical to the successful research, development and approval cycle of pharmaceuticals. Major applications include analytical instrumental analysis, such as high-performance liquid chromatography (HPLC), as well as pilot and full scale production of pharmaceuticals. Honeywell also offers reagents for DNA and RNA synthesis. Honeywell manufactures its solvents for the Turkish market at its production facility in Seelze, Germany.

The agreement with Pro-Lab expands Honeywell Burdick & Jackson's distribution network in Europe, Middle East and Africa. In Germany and Austria, Honeywell's high-purity solvents are distributed by OMNI Life Science; the Irish market is supplied by Reagecon Diagnostics; the Swiss market by Thommen-Furle; the markets in Sweden, Norway and Denmark by Saveen Werner.

For more information, visit www.burdickandjackson.eu or www.pro-lab.com.tr.

Honeywell's Health Care and Packaging business is part of Honeywell Specialty Materials, a global leader in providing customers with high-performance specialty materials, including fluorine products; specialty films and additives; advanced fibers and composites; intermediates; specialty chemicals; electronic materials and chemicals; and technologies and materials for petroleum refining.

Honeywell International (www.honeywell.com) is a Fortune 100 diversified technology and manufacturing leader, serving customers worldwide with aerospace products and services; control technologies for buildings, homes and industry; automotive products; turbochargers; and specialty materials. Based in Morris Township, N.J., Honeywell's shares are traded on the New York, London, and Chicago Stock Exchanges. For more news and information on Honeywell, please visit www.honeywellnow.com.

This report contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of fact, that address activities, events or developments that we or our management intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. Forward-looking statements are based on management's assumptions and assessments in light of past experience and trends, current conditions, expected future developments and other relevant factors. They are not guarantees of future performance, and actual results, developments and business decisions may differ from those envisaged by our forward-looking statements. Our forward-looking statements are also subject to risks and uncertainties, which can affect our performance in both the near- and long-term. We identify the principal risks and uncertainties that affect our performance in our Form 10-K and other filings with the Securities and Exchange Commission.

SOURCE Honeywell


'/>"/>
SOURCE Honeywell
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. 2009 H1N1 Flu Test From Quest Diagnostics Now CE Marked For International Distribution Under The Simplexa(TM) Brand Name
2. Mach 7 Technologies and Data Distributing Sign Agreement for U.S. Distribution of Enterprise Image Management Solutions
3. Misonix Announces New Distribution Agreement for Argentina
4. Millar Instruments and Transonic Systems, Suppliers of Gold Standard Pressure and Flow Products, Enter Into Mutual Distribution Agreement
5. Misonix Announces New Distribution Agreement For The United Arab Emirates (UAE)
6. Millar Instruments and Harvard Apparatus Improve Ability to Provide Customers With Total Physiology Solutions Through Joint Distribution Agreement
7. Misonix Announces New Distribution Agreement for Saudi Arabia and Other Middle Eastern Countries
8. Health Robotics Reaches 100% Asia-Pacific Coverage Through its New Exclusive Distribution Contract With BioRobotics in Korea
9. PLC Systems Reports Third Quarter 2009 Results; Announces Distribution Agreement for RenalGuard(R) in Brazil
10. PLC Systems Announces Distribution Agreement for RenalGuard(R) in Brazil
11. Sigma-Aldrich Enters Distribution Agreement With Stemgent, Inc. to Offer Lentivirus-Based Gene Delivery Products for Regenerative Medicine and Stem Cell Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2017)... 2017  Consumer reviews on the independent review site Consumer ... one company for hearing aids, ranking it higher than Miracle ... ... Consumers For Hearing Aids ... an online store that provides high performance, state-of-the-art, German-engineered hearing aids ...
(Date:9/9/2017)... Sept. 9, 2017  Eli Lilly and Company (NYSE: ... secondary endpoint data for lasmiditan, an investigational, oral, first-in-class ... statistically significant improvements compared to placebo in the Phase ... at the 18th Congress of the International Headache Society ... "The data presented today demonstrate lasmiditan,s potential to reduce ...
(Date:9/7/2017)... NuvoAir (formerly called Pond Healthcare Innovation), the company commercializing ... Pharma AG to distribute NuvoAir,s spirometry technology to physicians worldwide. ... platform and Novartis, commitment to address the unmet medical needs ... ... "We are ...
Breaking Medicine Technology:
(Date:9/21/2017)... Falls Church, VA (PRWEB) , ... September 21, ... ... Use Policy , **An FDAnews Management Report**, http://www.fdanews.com/products/54818-promotional-communication      , In the ... every edge they can get while staying in compliance with FDA rules. , ...
(Date:9/21/2017)... WA (PRWEB) , ... September 21, 2017 , ... ... technology using Microscan’s LVS 7510 at the Global GS1 Healthcare Conference 2017 in ... of the life-sciences industry for ensuring label quality and improving patient safety. ...
(Date:9/21/2017)... ... September 21, 2017 , ... FlipBelt, the fitness brand that ... detail to the athletic wear market with the launch of their FlipBelt Crops. , ... their essentials securely at their fingertips while at the gym, on the trail, or ...
(Date:9/20/2017)... ... September 20, 2017 , ... FirstAlign ( http://www.firstalign.com ), combines ... Artificial Intelligence (AI) thinking, announced today the launch of its revamped web presence. ... information that offers a more comprehensive understanding of the organization’s business and machine ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... and commercialization, has just released a new white paper discussing the benefits ... than ever about medical device, pharmaceutical, and combination product organizations making sure ...
Breaking Medicine News(10 mins):